patent.fyi
Applications  /  US 2026/0355217
United States Patent Application Publication

US 2026/0355217 A1

Published
Nov 12, 2026
Filed
Sep 22, 2023
Earliest date on the face
Sep 22, 2022
Classification
A61K 31/553
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.3Open geminal substitution

What ifWhat if two Re groups on the same carbon remain separate as methyl and hydroxymethyl groups?
Claim language“two geminal Re are taken together”

The methyl group occupies space near the attachment carbon, and the hydroxymethyl group presents a terminal oxygen for hydrogen bonding. Rotation about the hydroxymethyl carbon–carbon bond changes the position of that oxygen.

1.6Saturated chair ring

What ifWhat if ring A is a trans-1,4-disubstituted cyclohexane?
Claim language“C6-10 aromatic ring”

The saturated ring adopts a chair conformation, with both substituents equatorial in the lower-energy chair for typical bulky attachments. The two equatorial bonds project the attachments in opposite directions from the ring.

1.9Separate adjacent side groups

What ifWhat if adjacent ring positions carry separate methoxy and methyl groups with no bond between them?
Claim language“two adjacent Rd are taken together”

The methoxy oxygen provides a hydrogen-bond acceptor, while the methyl group fills space at the neighboring position. The parent ring holds the attachment sites next to each other, and the methoxy group rotates about its bond to the ring.

1.11Oxygen in the ring

What ifWhat if the shared carbon is part of an oxetane ring with oxygen opposite that carbon?
Claim language“a 3- to 7-membered carbocyclylene”

The shared carbon and two methylene units connect through the ring oxygen to form a four-membered heterocycle. The ring constrains the two bonds extending from the shared carbon, and the ether oxygen provides a hydrogen-bond acceptor.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference inhibitor for veterinary kinase assays

A formula (I′) compound serves as a reference inhibitor in a cell-free veterinary pharmacology assay. Parallel wells contain recombinant canine or feline HPK1, a peptide substrate, and ATP. A concentration series and matched vehicle wells establish a separate response curve for each enzyme, and no-enzyme wells establish the background signal.

Component substitution

Methylene phosphine oxide in the Q linker

A methylene phosphine oxide linker, —CH₂—P(=O)(CH₃)—, replaces a sulfone at the Q position of a cyclic formula (I′) analog. The methylene carbon attaches to one Q junction, the phosphorus attaches to the other, and an ether occupies Y. Chromatographic separation resolves the phosphorus stereoisomers when the two ring paths at phosphorus differ, and a cell-free HPK1 assay measures each fraction separately.

Parameter or scale variation

Miniaturized kinase assay with a concentration series

A 384-well plate holds 10 µL reactions containing recombinant HPK1, a peptide substrate, and ATP. Each compound occupies a 10-point, threefold dilution series that starts at 30 µM, with dimethyl sulfoxide held at 0.3 percent by volume in every well. The compound and enzyme incubate together for 15 minutes before substrate and ATP addition, and the plate reader measures an ADP-dependent signal after a 20-minute reaction.

Combination with existing systems

Kinase binding measured by surface plasmon resonance

An amine-coupled sensor surface holds recombinant HPK1 in one flow cell, and an activated and quenched surface occupies the reference flow cell. The instrument injects a concentration series of the formula (I′) compound through both cells, followed by running buffer to record dissociation. Reference subtraction and solvent correction produce sensorgrams that the instrument fits to estimate binding affinity.

Equilibrium dialysis coupled to mass spectrometry

An equilibrium dialysis unit holds the formula (I′) compound in plasma on one side of a semipermeable membrane and buffer on the other. After equilibration, liquid chromatography coupled to tandem mass spectrometry measures the compound in both chambers using matrix-matched calibration. The buffer-to-plasma concentration ratio gives the unbound fraction, and a buffer-only dialysis control measures loss to the membrane and chamber surfaces.

Automated or data-driven variant

Model guided selection of matched analogs

A software workflow encodes prepared analogs as molecular fingerprints and pairs them with measured HPK1 inhibition and aqueous solubility. A Gaussian process model ranks candidate pairs that differ at one substituent by predicted potency, solubility, and uncertainty. The software exports selected pairs and vehicle controls as a plate map for a liquid handler, then adds the measured results to the training set.

Specific version of a part

Two groups on phenyl

A phenyl group attached through carbon 1 carries fluorine at carbon 3 and methyl at carbon 4. Both substituents bond directly to the aromatic ring, and the remaining ring positions carry hydrogen.

Direct dimethylamino substituent

Res is a dimethylamino group, with L′ as a direct bond and both nitrogen substituents as methyl. The nitrogen bonds directly to the substituted group and accepts a proton in its neutral form.

Direct methyl sulfone group

Rd is a methylsulfonyl group with L′ as a direct bond and R′ as methyl. The ring bonds directly to sulfur, which carries two oxo groups that act as hydrogen-bond acceptors.

Two-carbon amide side chain

Rdd is —CH₂CH₂C(O)NHCH₃, with L″ as ethylene and the amide nitrogen bearing hydrogen and methyl. The amide carbonyl oxygen accepts hydrogen bonds, and the nitrogen-bound hydrogen donates them.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0202484 A1
Published
Aug 13, 2009
Filed
Jul 6, 2007
Class
A61K 38/21
Document BUS 8,507,507 B2
Published
Aug 13, 2013
Filed
Oct 15, 2010
Class
A61K 31/522
Claim 1
Document A
Document B
1.1each of the C6-10 aryl, 3- to 14-membered carbocyclyl, 3- to 14-membered heterocyclyl and 5- to 14-membered heteroaryl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 Re groups
The term “substituted” in reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, etc., for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”, “substituted heterocyclyl”, and “substituted carbocyclyl” means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
A · US 2009/0202484 A1 · ¶ 108
The term “substituted” in reference to alkyl, aryl, arylalkyl, carbocyclyl, heterocyclyl, and other groups used herein, for example, “substituted alkyl”, “substituted aryl”, “substituted arylalkyl”, “substituted heterocyclyl”, and “substituted carbocyclyl” means a group, alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
B · US 8,507,507 B2 · ¶ 81
1.2Re is independently selected from H, D, halogen, —CN, oxo, C1-8 alkyl, C1-8 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, -L′-OR′, -L′-NR′R″, —NO2, -L′-SR′, -L′-C(O)OR′, -L′-C(O)NR′R″, -L′-S(O)2R′, -L′-S(O)2NR′R″, -L′-OC(O)R′, -L′-OC(O)NR′R″, -L′-C6-10 aryl, -L′-3- to 14-membered carbocyclyl, -L′-3- to 14-membered heterocyclyl and -L′-5- to 14-membered heteroaryl, each of which is optionally substituted with 1, 2 or 3 Res
The term “substituted” in reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, etc., for example, “substituted alkyl”, “substituted alkylene”, “substituted aryl”, “substituted arylalkyl”, “substituted heterocyclyl”, and “substituted carbocyclyl” means alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent.
A · US 2009/0202484 A1 · ¶ 108
D2 is aryl or heteroaryl; n is 0, 1, or 2; each R3 and R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(═O)R8, —NR8S(═O)2R9, —NR8S(═
B · US 8,507,507 B2 · claim 2
1.3or two geminal Re are taken together with the atom to which they are jointly attached to form a 3- to 7-membered carbocyclyl or a 3- to 7-membered heterocyclyl, which is optionally substituted with 1, 2 or 3 Res
R2 is independently H, R1, R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups;
A · US 2009/0202484 A1 · ¶ 497
R6 and R7, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P; or
B · US 8,507,507 B2 · ¶ 24
1.4Res is independently selected from H, D, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -L′-OR′ and -L′-NR′R″
Typical substituents include, but are not limited to, —X, —R, —O−; ═O, —OR, —SR, —S−, —N2, —N+R3, ═NR, —CX3, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NHC(═O)R, —C(═O)NRR—S(═O)2O−, —S(═O)2OH, —S(═O)2R, —OS(═O)2OR, —S(═O)2NR, —S(═O)R, —OP(═O)(OR)2, —P(═O)(OR)2, —P(═O)(O−)2, —P(═O)(OH)2, —P(O)(OR)(O−), —C(═O)R, —C(S)R, —C(O)OR, —C(O)O—, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NRR, —C(S)NRR, —C(═NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is i
A · US 2009/0202484 A1 · ¶ 108
1.5Rd1 is selected from H, D, halogen, —CN, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, -L-OR′, -L-NR′R″, -L-C(O)NR′R″, -L-C6-10 aryl, -L-3- to 14-membered carbocyclyl, -L-3- to 14-membered heterocyclyl and -L-5- to 14-membered heteroaryl
R3 is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl;
A · US 2009/0202484 A1 · ¶ 5
1.6ring A is selected from C6-10 aromatic ring, 3- to 14-membered carbocycle, 3- to 14-membered heterocycle and 5-to 14-membered heteroaromatic ring
“Carbocycle” or “carbocyclyl” refers to a saturated, partially unsaturated or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle.
A · US 2009/0202484 A1 · ¶ 121
1.7Rd is independently selected from H, D, halogen, —CN, -L′-S(O)0-2R′, -L′-S(O)2NR′R″, -L′-S(O)NR′R″, -L′-OR′, -L′-NR′R″, -L′-C(O)OR′ and -L′-C(O)NR′R″
Typical substituents include, but are not limited to, —X, —R, —O−; ═O, —OR, —SR, —S−, —N2, —N+R3, ═NR, —CX3, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NHC(═O)R, —C(═O)NRR—S(═O)2O−, —S(═O)2OH, —S(═O)2R, —OS(═O)2OR, —S(═O)2NR, —S(═O)R, —OP(═O)(OR)2, —P(═O)(OR)2, —P(═O)(O−)2, —P(═O)(OH)2, —P(O)(OR)(O−), —C(═O)R, —C(S)R, —C(O)OR, —C(O)O—, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NRR, —C(S)NRR, —C(═NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is i
A · US 2009/0202484 A1 · ¶ 108
D2 is aryl or heteroaryl; n is 0, 1, or 2; each R3 and R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(═O)R8, —NR8S(═O)2R9, —NR8S(═
B · US 8,507,507 B2 · claim 2
1.8or Rd is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, -L′-C6-10 aryl, -L′-3- to 14-membered carbocyclyl, -L′-3- to 14-membered heterocyclyl and -L′-5-to 14-membered heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, 5, 6, 7 or 8 Rdd
R1 and R2 are each independently H, alkyl, substituted alkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, -alkylene-C(O)—O—R5, -(substituted alkylene)-C(O)—O—R5, -alkylene-O—C(O)—R5, -(substituted alkylene)-O—C(O)—R5, -alkylene-O—C(O)—O—R5, or -(substituted alkylene)-O—C(O)—O—R5;
A · US 2009/0202484 A1 · ¶ 5
R1 is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl
B · US 8,507,507 B2 · claim 1
1.9or two adjacent Rd are taken together with the atoms to which they are attached to form a 3- to 7-membered monocyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, a 6- to 10-membered spiro bicyclic heterocyclyl, or a 6- to 10-membered fused bicyclic heterocyclyl, and the 3- to 7-membered monocyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered spiro bicyclic heterocyclyl, or 6- to 10-membered fused bicyclic heterocyclyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7 or 8 Rdd
X2 is N; each non-hydrogen R5 may optionally connect to X1 to form an additional 5 to 8 membered carbocyclic or heterocyclic ring; each non-hydrogen R5 may optionally connect to D1 to form an additional 5 to 8 membered carbocyclic or heterocyclic ring;
B · US 8,507,507 B2 · claim 1
1.10Rdd is independently selected from H, D, halogen, —CN, —NO2, oxo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, -L″-OR′, -L″-NR′R″, -L″-C(O)OR′, -L″-C(O)NR′R″, -L″-S(O)0-2R′, -L″-S(O)2NR′R″, -L″-S(O)NR′R″, -L″-OC(O)R′, -L″-OC(O)NR′R″, -L″-C6-10 aryl, -L″-3- to 14-membered carbocyclyl, -L″-3- to 14-membered heterocyclyl and -L″-5- to 14-membered heteroaryl
Typical substituents include, but are not limited to, —X, —R, —O−; ═O, —OR, —SR, —S−, —N2, —N+R3, ═NR, —CX3, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NHC(═O)R, —C(═O)NRR—S(═O)2O−, —S(═O)2OH, —S(═O)2R, —OS(═O)2OR, —S(═O)2NR, —S(═O)R, —OP(═O)(OR)2, —P(═O)(OR)2, —P(═O)(O−)2, —P(═O)(OH)2, —P(O)(OR)(O−), —C(═O)R, —C(S)R, —C(O)OR, —C(O)O—, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NRR, —C(S)NRR, —C(═NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is i
A · US 2009/0202484 A1 · ¶ 108
D2 is aryl or heteroaryl; n is 0, 1, or 2; each R3 and R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, ═O, —OR8, —SR8, —NR9R10, ═NR8, ═NOR8, ═NNR8R9, —CN, —OCN, —SCN, —N═C═O, —NCS, —NO, —NO2, ═N2, —N3, —NR8C(═O)R9, —NR8C(═O)OR9, —NR8C(═O)NR9R10, —C(═O)NR9R10, —C(═O)OR8, —OC(═O)NR9R10, —OC(═O)OR8, —C(═O)R8, —S(═O)2OR8, —S(═O)2R8, —OS(═O)2OR8, —S(═O)2NR9R10, —S(═O)R8, —NR8S(═O)2R9, —NR8S(═
B · US 8,507,507 B2 · claim 2
1.11or CRddRdd forms a 3- to 7-membered carbocyclylene or a 3- to 7-membered heterocyclylene, which is optionally substituted with 1, 2 or 3 groups selected from: H, D, halogen, C1-6 alkyl, C1-6 haloalkyl, —OR′ and —NR′R″
R2 is independently H, R1, R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups;
A · US 2009/0202484 A1 · ¶ 497
1.12or two non-adjacent Rdd are taken together to form a C1-8 alkylene, which is optionally substituted with one or more of the following substituents: H, D, halogen, CN, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, -L″-C6-10 aryl, -L″-3- to 10-membered carbocyclyl, -L″-3- to 10-membered heterocyclyl and -L″-5- to 10-membered heteroaryl or two adjacent Rdd are taken together with the atoms to which they are attached to form a 3- to 7-membered carbocyclylene, a 3- to 7-membered heterocyclylene, a phenylene, or a 5- to 6-membered heteroarylene, which is optionally substituted with 1, 2, 3 or 4 substituents selected from: H, D, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, —OR′ and —NR′R″ L and L′ are independently selected from covalent bond, —O—, —S—, —NR′—, —S(O)2—, —C(O)—, —C(O)O—, —C(O)NR′—, —OC(O)—, —OC(O)NR′—, —N(R′)C(O)O—, —N(R′)C(O)— and —N(R′)S(O)2— or, L or L′ is C1-8 alkylene, in which one or more methylene units are optionally and independently replaced by —C(R′)2—, —N(R′)—, —N(R′)C(O)—, —C(O)N(R′)—, —N(R′)S(O)2—, —S(O)2N(R′)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)—, or —S(O)2— R′ and R″ are independently selected from H, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, -L″-C6-10 aryl, -L″-3- to 14-membered carbocyclyl, -L″-3- to 14-membered heterocyclyl and -L″-5- to 14-membered heteroaryl or, R′ and R″ are taken together with the N atom to which they are attached to form a 3- to 14-membered heterocyclyl L″ is selected from covalent bond, —O— and —S— or, L″ is C1-8 alkylene, which is optionally substituted with one or more R, and one or more methylene units in the C1-8 alkylene are optionally and independently replaced by —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)—, or —S(O)2— R is independently selected from H, D, C18 alkyl, C18 haloalkyl, -Ld-3- to 10-membered carbocyclyl and -Ld-3- to 10-membered heterocyclyl or two R are taken together with the C atom to which they are jointly attached to form a 3- to 10-membered carbocyclylene or a 3- to 10-membered heterocyclylene Ld is independently selected from covalent bond and C1-8 alkylene f=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 wherein each of the above groups is optionally deuterated, up to completely deuterated.
L1 is a covalent bond, arylene, substituted arylene, heterocyclylene, substituted heterocyclylene, carbocyclylene, substituted carbocyclylene, —S—, —S(O)—, S(O)2, —NR5—, or —O—;
A · US 2009/0202484 A1 · claim 1
X1 is alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocyclylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, —NR8—, —O—, —C(O)—, —S(O)—, —S(O)2—, or a covalent bond;
B · US 8,507,507 B2 · ¶ 15

An empty cell means only that no passage was reproduced there.

Statements in these documents
This application relates generally to compounds and pharmaceutical compositions which selectively activates toll-like receptor 7 (TLR7), and methods of making and using them.
A · US 2009/0202484 A1 · ¶ 1
Accordingly, the present application is directed to compounds and pharmaceutical compositions, and methods for use in preventing or treating diseases or conditions characterized by Toll-like receptor 7 (TLR7) activation in patients.
A · US 2009/0202484 A1 · ¶ 4
This application relates generally to biaryl purine and 3-deazapurine derivatives and pharmaceutical compositions which selectively modulate toll-like receptors (such as TLR-7), and methods of making and using such compounds.
B · US 8,507,507 B2 · ¶ 2
Agonists of TLR-7 are immunostimulants and induce the production of endogenous interferon-a in vivo.
B · US 8,507,507 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355217 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355217/, SHA-256 38ede63d0d1af1f7ae39f0764a145f2d05adf862c6d26214732c5b2120a816a3
First published
Permanent addresshttps://patent.fyi/US20260355217/
Content fingerprint (SHA-256)38ede63d0d1af1f7ae39f0764a145f2d05adf862c6d26214732c5b2120a816a3
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi